THC gummies are edible candies infused with THC (delta-9-tetrahydrocannabinol) and are one of the many edible forms of the cannabinoid extracted from the cannabis plant. THC gummies usually have a gelatin or pectin base with sugar, flavors and fruit extracts, and a dose of cannabis distillate or oil. Since cannabis extracts are oil soluble, to stabilize and distribute THC evenly throughout the gummy matrix, manufacturers use fats and oils. THC gummies are consumed just like any other food, and for edibles to take effect, they must be digested. Edibles take longer to take effect, and have a delayed onset of action, and users can usually expect effects to take 30-120 minutes (or longer) to set in.
This is the case due to individual differences in factors such as body mass, and metabolic rate. Just like edibles, smoking and vaping deliver the effects of cannabinoids almost immediately, and THC gummies usually take much longer to take effect compared to smoking and vaping.After digestion, compounds enter the bloodstream via the intestinal wall and the portal vein, and are transported to the liver. First-pass metabolism, which occurs in the liver, converts standard delta-9-THC to 11-hydroxy-THC, a more potent psychoactive metabolite.
This accounts for why oral consumption of THC-containing products results in higher, longer lasting psychoactive effects when compared to inhalation.Effects of ingestion can include: deep physical relaxation, altered time perception, euporia, and dry mouth. Other less common effects can include drowsiness, impairment of short-term memory, reduced coordination, enhanced perception of smell and peripheral vision, anxiety, and panic attacks. Because the liver metabolizes THC to 11-hydroxy-THC, and because of the prolonged and reduced Clearance of this metabolite, healthcare professionals recommend starting with low doses and to wait long to avoid over-stimulating effects.
Understanding Australia’s TGA regulations for THC gummies begins with acknowledging that nationwide, the law prohibits the production, sale and possession of recreational cannabis edibles. The TGA places THC gummies and other edibles in the same category as other products that contain THC, and places them in Schedule 8. As such, THC gummies and other edibles are classed as prescription-only, unapproved therapeutic goods. As such, these oral formulations cannot be purchased at a pharmacy or online. As with all other unapproved prescription medications, they can only be legally acquired through a formal medical process.
In this case, a medical practitioner would first need to assess and determine that a patient has a chronic condition and that standard first-line therapies have been ineffective. Only then would the practitioner be able to submit a Special Access Scheme – Category B (SAS-B) request to the TGA to gain authorization for an individual patient to access THC for medical purposes. Alternatively, the practitioner could also use the Authorised Prescriber pathway, for which they must go through an approval process. Unlike the general approval process for other medications, where a certain level of market saturation is permitted, the TGA evaluates each individual case, based on the principle of the risk-benefit analysis, to ensure that medications are being safely distributed. The quality and safety of all THC products are strictly monitored.
To lawfully possess medication, patients must store their mediation in its original pharmacy-dispensed condition. This is to avoid legal complications. There are strict zero-tolerance limits for driving under the influence of drugs in all states. This means that no trace of THC can be found in the driver in order to legally drive. This is the case even if the THC was obtained through a legal medical marijuana prescription. There are strict regulations in Australia and cannabis dispensation is strictly monitored to control medical cannabis access. This ensures that oral THC therapies remain strictly controlled rather than open to the general public.
The Legal Status of THC Gummies in Australia Explained
In Australia, the distinction between the recreational and medical uses of cannabis means THC Gummies are legal only in certain circumstances. THC Gummies are not available for recreational purchase and use in Australia. Only medical cannabis products can be purchased in a controlled and regulated manner. The sale and supply of cannabis for recreational use is illegal throughout Australia. Some jurisdictions have decriminalised and/or adopted personal possession rules for cannabis, but these do not make THC Gummies legally available for recreational purchase and use. Access to medicinal cannabis products is through the Special Access Scheme (SAS) and/or Authorised Prescriber Scheme. The product is prescribed by a registered medical practitioner or nurse practitioner.
This provides a legal framework for the supply of a product containing cannabis for therapeutic use, whereas the supply of THC products for recreational use is illegal. Selling a product as a Gummy does not legalize it. Similarly, the term “medicinal” does not necessarily make a product legal. Australian consumers must understand the legal framework in which the supply of a THC product occurs, and whether it is supplied as a medicinal product. Ultimately, the legality of the product is determined by the framework in which it is supplied, not simply the name of the product or how it is packaged.
In addition, individuals looking into THC Gummies Australia need to know that medicinal cannabis does not mean open access to THC sweets. The TGA recognizes medicinal cannabis in different forms such as oral liquids, capsules and sprays as well as dried cannabis. Most medicinal cannabis products are not listed on the ARTG. Even though these products can be prescribed through approved access pathways, they are still subject to the therapeutic goods requirements. A prescription does not mean a product has been assessed and approved by the TGA. THC Gummies are just one example where the prescribed medicinal cannabis must be obtained through an Australian registered pharmacy rather than an online pharmacy, vape shop or tobacconist.
This distinction is particularly important because the online advertising of THC Gummies makes recreational products appear as legal medicines. Just because a THC Gummy is sold as a food product or as a recreational product, doesn’t mean it becomes a lawful product because it is labeled with a dosage, a laboratory test claim or has a description that sounds medicine like. State and territory law also governs prescribing, possession and driving with THC medicinal cannabis.
THC can affect a person’s ability to drive, and just because someone has a prescription, it doesn’t remove all the driving restrictions. A prescription simply means a person has access to the medicinal cannabis through an approved access pathway. THC Gummies are not lawfully sold in the retail market and prescribed medicinal cannabis is. This is the reason why authorized and regulated medicinal cannabis has various forms, packaging and marketing claims that seem to support the reason for the lawful access. It is not the ‘gummy’ form that determines legality.
Navigating TGA Regulations for Edible Cannabis Product
The regulation of THC Gummies in Australia is different from the regulation of other edible cannabis products. THC Gummies are classed as ‘medicinal cannabis’ and are therefore regulated under the medicinal cannabis framework. Other medicinal cannabis products, which are unapproved therapeutic goods, are not listed on the Australian Register of Therapeutic Goods (ARTG), and does not make the product illegal. The Therapeutic Goods Administration (TGA) regulates the access of unapproved medicinal cannabis products under the Special Access Scheme (SAS) and the Authorised Prescriber Scheme (AP). Clinical trials also provide regulated access. For THC Gummies, the legal pathway is dependent on therapeutic use and authorised supply.
A product is not automatically legal just because it is labeled with a dosage. Also, just because a product is sold online, that doesn’t mean that product is approved or lawful in Australia. The TGA also monitors the products supplied under the Special Access Scheme and the Authorised Prescriber Scheme. The TGA’s current product lists are also a source of information for prescribers and pharmacists. This information helps separate regulated medicinal cannabis products from ordinary edibles that are sold in the marketplace. In effect, regulation is dependent on the therapeutic good framework, rather than the appearance of the product.
Most medicinal cannabis products that contain THC are classified as Schedule 8 medicines. Schedule 8 medicines are Controlled Drugs. There are differences in how State and Territory laws give practical legal effect to these scheduling rules. THC Gummies are covered here because a Schedule 8 classification has various implications (such as how a medicine is prescribed, possessed, stored or supplied). There are further controls when a medicine is imported. Generally, medicinal cannabis that is prohibited from import to Australia, requires an import license from the Office of Drug Control (ODC) and a permit for each consignment. A person cannot import controlled medicinal cannabis for personal use. The Personal Importation Scheme (PIS) excludes controlled substances and vaping products.
A useful compliance point is that, for importing therapeutic goods, permission to import and the TGA authority are two separate things. An importer has to satisfy both of these requirements. The Therapeutic Goods Act states that unapproved medicinal cannabis importations for SAS or AP supply must comply with the therapeutic goods requirement and be secured until released for patient use. This means that importing THC Gummies does not create a legal import pathway. The legal process to import medicinal cannabis depends on the product, its constituents, intended therapeutic use and the required approvals in Australia.
Special Access Scheme (SAS-B) vs. Authorised Prescriber Scheme
There are regulated pathways for approved use of THC gummies and other unapproved medicinal cannabis products in Australia. The Special Access Scheme Category B (SAS-B) is used by health professionals to access unapproved products for an individual patient. The doctor assesses the patient and determines whether an unapproved product may be suitable. The doctor then assesses approved therapies and provides justification for the unapproved product by explaining why approved therapies may not be suitable. The doctor prepares a clinical justification. This document describes the patient’s condition, other therapies the patient has been offered or is considering, and expected benefits of the unapproved therapy. It also describes the possible risks.
The doctor submits the request through the TGA’s SAS and AP Online System. The doctor cannot legally prescribe the product until it has been approved by the TGA. The TGA states each Category B application is assessed individually and that processing time is approximately two to five working days. If the TGA requests additional information, processing time may increase. Approval is for the practitioner and does not mean the product is approved for general use. This is important for patients who inquire how doctors can legally prescribe THC Gummies. THC Gummies are individually assessed based on the prescribing doctor and the applicable state or territory laws. A product approved by the TGA does not mean it has been added to the Australian Register of Therapeutic Goods (ARTG). Most medicinal cannabis products are unapproved therapeutic goods.
The Authorised Prescriber (AP) scheme allows an eligible medical practitioner to prescribe an unapproved therapeutic good to multiple patients. Each product, indication and dosage form must first be evaluated by the medical practitioner. The practitioner must then determine if the therapeutic good and indication are on the TGA’s established-history-of-use list. If they are, the practitioner can take that pathway to prescribe it. If not, the medical practitioner must take the standard AP route. The standard AP pathway requires the practitioner to obtain either Human Research Ethics Committee (HREC) approval or endorsement by the relevant Specialist College, before making the application to the TGA. The practitioner makes the application through the SAS and AP Online System.
The TGA evaluates the application and may grant an authority letter to the medical practitioner. The authority letter outlines the terms and conditions, including the patient class, indication, therapeutic good and dosage form, among other things. The medical practitioner must meet a number of continuing obligations. These include reporting the number of patients within the authorized class every six months, and reporting any suspected adverse events or product defects to the TGA. Under the simplest terms, for patients, the main difference between SAS-B and AP is that SAS-B provides access to an individual patient, while AP provides access to a group of patients. The difference is based on regulatory requirements and clinical situations. THC Gummies are not the deciding factor.
State-by-State Cannabis Laws: Possession, Travel, and Penalties
Australian laws governing cannabis are a combination of Commonwealth and state/territory laws. This is important when considering transportation of prescribed THC Gummies across state lines. Possession rights are not extended automatically to other states with a prescription. Each state/territory has its own medicines and poisons scheduling. Most medicinal cannabis products are scheduled as a controlled drug (CD) of dependence (Schedule 8 in the majority of cases). As such, patients should transport their THC Gummies in their pharmacy packaging and have the dispensing label visible. A copy of the prescription or letter from the prescribing doctor would also be prudent.
NSW specifically states that travellers carrying Schedule 8 cannabis medicines should check the laws of the destination state/territory. In Queensland, possession of cannabis medicines is allowed only if it is lawfully supplied. Other serious Schedule 2 cannabis offences (eg, supplying, cultivation) attract serious penalties. WA also controls THC medicinal cannabis within the same restrictions as other medicinal cannabis. The state also states that the presence of THC in the body while driving means a person cannot legally drive. All of this means there is no interstate blanket exemption. Each state/territory’s laws govern transport of THC Gummies, and the prescription, labelling, quantity and restrictions of the destination state all need to be considered. A prescription provides a major legal protection, but restrictions still exist in each state/territory.
Patients should know the state and territory laws regarding THC Gummies before crossing a border. The TGA states that there are differences in state and territory requirements for Schedule 8 medicines. This means that additional prescribing or possession conditions may apply. Therefore, there is no single “legal threshold” for patients carrying THC Gummies in Australia. The legal amount is usually linked to the prescription and the controls of the state. Patients should never rely on recreational limits for THC Gummies when transporting prescribed medicine. The recreational limits do not convert cannabis into a prescribed medicine, and do not allow commercial supply.
The safest way to travel is to carry only the amount of medicine prescribed. The medicine should be in its original pharmacy container. Patients should also carry supporting documents. Patients should check the medicines and poisons regulator of the state they are travelling to. This is important for all of NSW, VIC, QLD, WA, SA, TAS, ACT and NT. Patients should also consider separating interstate and international travel. THC Gummies should be carried only as prescribed medicine, not as confectionery, or recreational cannabis.
Medical Access, Prescriptions & Patient Eligibility
Obtaining legal access to THC gummies in Australia involves undergoing a formal clinical evaluation by an Australian-registered medical practitioner or nurse practitioner. Patients cannot self-diagnose and are not able to order the oral products online. To be eligible, patients must suffer from a chronic medical condition for a minimum of 3 months, such as chronic non-cancer pain, severe muscle spasticity from multiple sclerosis, chemotherapy-induced nausea and vomiting, or palliative care symptoms which are resistant to other treatment options. It is also mandated that national clinical guidelines be followed and, therefore, standard first-line therapies must also have been attempted and ineffective prior to cannabinoid interventions.
Practitioners, therefore, also screen patients for absolute contraindications which may include a personal or family history of a psychotic disorder, unstable cardiovascular disease, or severe hepatic impairment, or if the patient is pregnant or breastfeeding. Additional clinical scrutiny must be taken with patients who are under the age of 18 and over the age of 65 due to neurological sensitivity. The treating clinician defines an initial dose and benchmarks follow-up visits to assess therapeutic progress.
Present prescribing regulations largely rely on Pathways administered by the Therapeutic Goods Administration (TGA). This means that while a prescription is processed, a medical practitioner can source the THC/CBD gummies from an established network of Authorised Prescribers (APs) or obtain Special Access (SAS-B) approval. Unlike most bulk imported prescribing, practitioners must provide justification as to why they are prescribing a gummy format and provide evidence as to why they are prescribing an unapproved product.
Upon obtaining the necessary approval, the practitioner issues a controlled (Schedule 8) prescription. Patients take this prescription to compounding pharmacies to formulate the gelatin or pectin base, under Therapeutic Goods Order No. 93 (TGO 93) specifications. Pharmacists strictly monitor availability of the prescription. This ensures that individuals at risk of chemical/physical dependency are protected, and that the medical needs of legitimate consumers are met with consistent, high quality and batch-tested therapeutic good oral products.
How to Get a Legal Prescription for THC Gummies in Australia
Legal THC Gummies in Australia begin with a consultation with an Australian registered doctor or nurse practitioner. There is no separate patient application process to the TGA. The prescribing practitioner makes the clinical decision. THC gummies are not first line treatments. The practitioner considers if other therapies have been used and also other treatments that could be used prior to considering an unapproved medicinal cannabis product. Once all of this information has been assessed and if THC gummies are appropriate, the practitioner chooses the most appropriate product and access pathway.
If the product is unapproved the practitioner is likely to use the Special Access Scheme. The most common pathway is the Authorised Prescriber Pathway. Your GP can be your first point of contact, or you can go to a legitimate medicinal-cannabis clinic. Be cautious of websites that promise a quick prescription. The TGA does not have a list of prescribers for medicinal cannabis. All registered doctors can make an independent clinical decision about medicinal cannabis.
Telehealth is a convenient option to discuss THC Gummies with an Australian healthcare practitioner. It requires an authentic clinical assessment. Make your medical records, history, treatments, and current medications available to the practitioner. The practitioner will make the determination as to whether medicinal cannabis is appropriate. If an unapproved product is suggested, the practitioner will complete the required process with the TGA. The practitioner will assess access for the individual under SAS-B. Depending on the state and territory requirements, approval may involve both the Commonwealth and that jurisdiction.
The practitioner, once the required approvals are obtained, issues a prescription. The patient then takes the prescription to a registered pharmacy. Unapproved medicinal cannabis products are ordered and delivered by the pharmacy. The patient should be aware that a prescription does not mean the TGA has assessed the product for safety and effectiveness. Most unapproved medicinal cannabis is privately paid and is not covered by the PBS. A prescribed medicinal cannabis product from a registered practitioner through a legitimate and required approval is the difference between legal and illegal medicinal cannabis. This process is the same for THC Gummies.
Qualifying Medical Conditions for Medicinal Cannabis
There are currently no set medical conditions that allow patients in Australia to access THC Gummies. Decisions around access to unapproved medicinal cannabis are made by the practitioner. In doing so, the practitioner considers the patient’s clinical condition, other treatments, anticipated benefits, and potential risks. Areas where medicinal cannabis may be clinically appropriate include some chronic pain conditions, including neuropathic pain. Sleep disorders, including in some cases anxiety, may also be considered. Certain medicinal cannabis products to treat refractory anxiety and sleep disorders in adults are authorized by the Therapeutic Goods Administration of Australia. There are no TGA authorized products for Anxiety and Sleep Disorders in the general population.
Consideration can be given to the use of medicinal cannabis in epilepsy and some Multiple Sclerosis conditions. Medicinal cannabis can also be considered in the context of Palliative Care. Access to THC Gummies is mainly determined based on the requirements of the individual patient. Consideration is also given to whether an approved treatment may also be more appropriate in the circumstances. This helps distinguish between genuine therapeutic access to medicinal cannabis from claimed automatic access for a range of conditions.
Whether a person is eligible for THC gummies is based on clinical judgement rather than a simple checklist. People eligible to discuss medicinal cannabis include those with chronic conditions such as pain, anxiety or sleep disorders. People eligible to discuss medicinal cannabis also include those with palliative care needs. When a qualified practitioner considers a person eligible to discuss medicinal cannabis, they also take into account the person’s condition and treatment. They also take into account other prescribed or unprescribed medicines and the possibility of adverse interactions. The TGA states that, prior to considering access to an unapproved medicinal cannabis product, a practitioner should evaluate available ARTG-listed treatments. This is particularly relevant to THC-containing medicines. THC may have psychoactive effects and may not be suitable for all patients.
A practitioner weighs up the expected therapeutic benefit versus the risk. Information on the TGA website states that there are pathways for certain medicinal cannabis products for patients with refractory chronic pain, refractory anxiety, refractory sleep disorders and cancer pain. Not all THC gummies products would fall under these pathways. It also depends on the formulation. Some products contain a predominance of CBD and some contain a combination of CBD and THC. Patients should speak with their qualified practitioner about the formulation. The most appropriate question to ask is not “Do I have a qualifying condition?”. The most appropriate question to ask is “Does my medical history support clinically justified medicinal cannabis treatment?” Understanding this would help a person understand the medicinal cannabis access scheme in Australia.
The Role of Compounding Pharmacies in Dispensing THC Edibles
In Australia, THC Gummies are different from other confectionery. Most medicinal cannabis products are unapproved therapeutic goods, meaning they require an approved access pathway to be prescribed and supplied. The TGA confirms patients cannot make requests for access themselves. It is the health practitioner’s role to make the clinical decision and use the relevant pathway. A prescription is then issued and taken to a pharmacy to order the product. This is the main reason standard retail pharmacies do not stock THC Gummies. THC is an unapproved medicinal cannabis product. It is regulated with a number of special conditions.
The TGA also maintains a product list to assist pharmacists in identifying the correct prescribed active ingredient, and to determine under which category (SAS or Authorised Prescriber) the product has been prescribed. Compounding a medicinal cannabis product is different, as it means preparing the product in the form and strength required for an individual patient. In this situation, the TGA states that the ordinary exemption for extemporaneous compounding does not apply to medicinal cannabis products. Other legislations may cover the situation and allow compounding in certain conditions. For this reason, patients cannot assume a pharmacy can compound cannabis-infused gummies.
The legal process for supplying THC Gummies starts at the prescriber’s office, not the pharmacy counter. A registered medical practitioner or a nurse practitioner reviews the patient’s case, determines the clinical need and appropriateness of medicinal cannabis, and prescribes the product. In the case of an unapproved product, the practitioner follows the TGA pathways, for example, the Special Access Scheme (SAS) or Authorised Prescriber Scheme, to gain access to the product. Approval, notification or authorization must be in place prior to the prescription being supplied. The prescription is then brought to an Australian registered pharmacy. The pharmacist evaluates the prescription and is authorized to supply the product if a regulatory requirement is in place. The pharmacy may order the product from the supplier.
The TGA states that the unapproved medicinal cannabis products should only be purchased from an Australian registered pharmacy. There may be specialty pharmacies that have experience in compounding certain medicinal cannabis products. This does not allow the specialty pharmacy to legally compound THC Gummies. Laws vary between the federal and state/territory governments of Australia, as well as prescription, patient/product/cannabinoid nature and form, and other factors. There are comprehensive professional standards in compounding medicinal cannabis that describe the appropriate equipment, licensing, personnel, training, and standards required. THC Gummies are included in these standards. Pharmacists cannot manufacture any THC edible based on a prescription. As per the Therapeutic Goods Act 1989, if a prescription is in order, this does not permit the pharmacy to manufacture the product. Patients should enquire from the pharmacy if THC Gummies are being lawfully supplied.
Cost Breakdown: Doctor Consultations, TGA Approvals, and Product Pricing
The price of THC Gummies through Australia’s medicinal cannabis system varies for each patient. There is no set national price. The first expense is typically the medical consultation. The cost of the consultation depends on the clinic and the practitioner (e.g. GP or specialist). Some clinics charge separate fees for follow-up appointments or administration. Patients should ask about the total price (including potential extraneous costs) before booking an appointment. The TGA does not charge a fee for SAS-B or Authorised Prescriber applications. However, that doesn’t mean the overall treatment is free.
The TGA says the overall treatment costs are covered by the patient or a third-party payer. Healthdirect also says the costs of medicinal cannabis treatment can range from hundreds to thousands of dollars each year. THC Gummies are just one treatment option for a variety of conditions and symptoms. When considering THC Gummies, patients should consider the total cost of the treatment, rather than the consultation cost. THC Gummies can have a significant impact on a patient’s budget due to variance in the number of gummies in a package (i.e. larger package does not mean lower cost).
Private health insurance usually doesn’t cover THC Gummies. Most unapproved medicinal cannabis products are not PBS-listed. TGA has confirmed that only registered medicinal cannabis products that meet the requirements can get PBS coverage and currently, only Epidyolex is in the list of registered medicinal cannabis products. Private health insurance policies differ, and therefore patients should contact their insurance company to check if consultations or products are covered. Out of hospital medical services are generally not covered by private health insurance, and pharmacy costs also require attention.
Unapproved medicial cannabis products are usually ordered by the pharmacy. Because of this, the pharmacy may apply their own dispensing or handling charge. PBS dispensing fees are not related to the prices of THC Gummies. Patients should contact the pharmacy for the price of the THC Gummies, dispensing charge and delivery fee. In the end, the total cost of the THC Gummies prescription, along with the cost of ongoing consultations and pharmacy fees, should be taken into consideration for budgeting.
Pharmacology, Dosage & Safety Profiles
Clincial pharmacology of oral THC gummies is different from the pharmacology of smokeable/vaporable cannabis due to the distinct means of human digestive processing. Edible THC products are metabolized in the same way as all other oral medicines. Delta-9-THC is absorbed in the gut and is carried via the portal vein to the liver. This is the first of multiple passage metabolisms in the liver (also known as first-pass metabolism). In the liver, cytochrome P450, specifically CYP2C9 and CYP3A4 enzymes, metabolize delta-9-THC to 11-hydroxy-THC. This active metabolite can cross the blood-brain barrier and is more potent and efficient than delta-9-THC. The onset of the psychoactive effect of THC occurs between 30-120 minutes post-ingestion, and the therapeutic effects occur between 1-2 hours post-ingestion.
Oral bioavailability of THC is between 4-12%. The absorption of THC is enhanced in the presence of dietary fats. Once absorbed, THC is carried by the blood stream to all areas of the body including the brain. Cannabinoids affect neurotransmission by modulating the release of pain and other neurotransmitters, and altering motor functions. Clinical dosage strategies are extremely cautious due to the prolonged duration of action of oral THC gummies, which can be up to 8 hours. Australian medical professionals start patients on extremely low doses of oral THC (i.e. fractions of a mg) in order to determine the individual threshold of the patient and reduce the risk of adverse psychiatric effects.
Some side effects reported during clinical monitoring include transient dry mouth, mild dizziness, somnolence, altered spatial coordination, and temporary tachycardia. Some patients report profound anxiety, paranoid ideation and transient cognitive impairment. Unmonitored doses can also lead to orthostatic hypotension. Because of the delta-9-THC metabolites in the system, patients are impaired for longer than what is measured, and they can test positively on roadside drug screenings. This means that patients are still legally impaired to operate any sort of machinery, and therefore should not operate motor vehicles or heavy machinery.
Because of sedation risks when using oral cannabinoids with central nervous system depressants and/or alcohol and/or specific hepatic enzyme inhibitors, patients should avoid using these with those drugs. Because of these problems, patients are tracked closely with structured follow-up appointments to ensure therapeutic benefits outweigh the risks. This is especially important due to patients being on the oral cannabinoids for an extended period of time due to strict prescription monitoring.
Oral THC Pharmacokinetics: Why Edibles Hit Differently Than Vapes or Flower
THC Gummies deliver a different experience from smoking or vaping cannabis for two reasons. First, the digestive system can’t break down THC the same way the lungs can. That means THC Gummies take longer to kick in. Second, the liver breaks down and metabolizes THC to other forms before it can reach the brain. One of those forms is 11-hydroxy-THC (11-OH-THC). 11-OH-THC is even more psychoactive than delta 9 THC and explains some of the differences between the effects of oral cannabis and smoked or vaped cannabis.
The onset of oral THC can vary from 30 minutes to 2 hours, although this can be influenced by many factors including the composition of the edible, how full your stomach is, the dosage, the individual’s metabolism and other factors. THC Gummies also show pharmacokinetic variability due to the digestive system. That means the strength of the THC Gummy can’t always be relied on to predict how strong the effects will be and when those effects will be felt.
THC Gummies and other forms of oral cannabis have a longer pharmacodynamic window compared to smoked or vaped cannabis. Effects from edibles may begin as late as 1.5 to 4 hours after consumption and last as long as 8 hours. Some evidence suggests some preparations can lead to effects lasting as long as 5-8 hours. It is generally understood that effects from smoked or vaped cannabis occurs quicker and lasts less time than oral cannabis.
One of the reasons oral administration behaves differently from smoked or vaped administration is the liver’s first-pass conversion of Delta-9-THC into 11-OH-THC. A commonly over looked fact is that THC gummies can lead to low measured blood THC levels and still be effective. In the case of THC gummies, blood THC levels may not be a great indicator for how impaired an individual may be. Further, since it takes longer for edibles to fully take effect, some individuals may take additional doses before the first dose has a fully taken effect, increasing the risk of adverse effects.
Finding Your Dose: Titration Strategies for Medical THC Gummies
Medical supervision is required to determine the right dose of THC Gummies for a patient. The Therapeutic Goods Administration (TGA) suggests a ‘start low, go slow’ approach for all medicinal cannabis. There is no single THC dose that is right for every patient. Medical history, previous exposure to cannabis, sensitivity to side effects, other medications, and age are some of the factors that a clinician takes into account when determining the right dose for a patient. Some patients may need to start at a lower dose (microdose) than what is normally prescribed.
For example, 2.5mg is a lower dose than 10mg; however, these doses are purely examples to illustrate an idea and are not universal. The TGA states that for oral cannabis, one must be patient, as the onset is typically between 30-90 minutes. It can take two to four hours to experience the full effects. These effects can last for many hours. It is extremely important to not take additional doses too quickly as this can increase adverse effects. The first dose, even if taken many hours earlier, is not completely metabolized. Patients are advised to adhere strictly to their prescribed schedule. Increasing the dose simply because effects are not immediate is incorrect.
A dosage journal captures relevant information for THC Gummies treatment. It allows patients to document prescribed dosages, time of administration, food intake, symptom severity, benefit and adverse effects, sleep quality, and other relevant info. The American Gastroenterological Association pointed out that using a dosage journal helps prescribing doctors see if the dose prescribed brings sufficient benefit to the patient, and if adverse effects appear after dose increase.
It is recommended that the TGA-permitted THC products be prescribed in the lowest effective dose to provide benefit, and increase gradually as needed. A dose that worked for one patient may not work for another. Different patients may require different doses to achieve the desired benefit. The lowest effective dose should be prescribed to avoid adverse effects, and the goal of using a dosage journal is to show response to treatment, not just chasing higher doses.
Potential Side Effects and Risks of High-THC Edibles
Consuming too much THC can amplify and extend the effects of THC Gummies. The effects of THC Gummies are slower to set in. The effects of THC Gummies can take as long as two hours to fully take effect. This delay can result in a person believing that they have not ingested enough THC and taking more in the process. Taking THC Gummies can result in temporary Anxiety, Nausea, Sedation and a rapid Heart Rate. THC Gummies can also result in more severe effects such as Hallucinations, Psychosis and Cognitive Disturbance. The term “greening out” has been used to describe a bad reaction to THC Gummies.
Calling it “greening out” is not a recognized medical diagnosis. A person who is “greening out” should go to a safe and calm environment. They should not drive or operate machinery. They should also avoid taking more THC Gummies and not take alcohol or other recreational drugs. “Greening out” can last for a long time and may result in Chest Pain and problems with Breathing. A person may lose Consciousness and experience Seizures. If symptoms are severe and/or result in loss of Consciousness and/or Seizures, they should call Emergency Services. (In Australia this is Triple Zero (000)). Patients should contact their medical prescribers if they experience an Adverse Reaction.
Another important consideration for THC Gummies is drug interactions. THC and CBD can be metabolized through liver enzyme systems. They can interact with other medicines using the same pathway. The TGA reports that clinical data on most cannabinoid drug interactions is limited. Therefore, prescribers should review a patient’s complete medication list prior to treatment and monitor for any changes. Of particular concern are medications which cause sedation, or affect the central nervous system. THC can worsen the effects of these medicines, and vice versa. Unwanted effects can occur with the combined use of alcohol and other medicines. There are a number of circumstances where prescribers are advised to use caution when prescribing medicinal cannabis containing THC.
These include active or previous psychotic disorder, active mood or anxiety disorders, pregnancy, breastfeeding and unstable cardiovascular disease. It is important to note this does not mean every patient in these situations has the same risk level. The prescriber makes an individual assessment for each patient. Patients should not stop their medication to manage anxiety or a fast heart beat without talking to their prescriber first. They should tell their prescriber about unwanted effects as soon as it happens. One main concern with the use THC Gummies is a discrepancy can occur between when a dose is taken and when the full effects of the dose is felt.
Tolerance, Dependence, and Withdrawal Risks with Regular THC Consumption
It is common for users of THC Gummies to develop a tolerance for THC. Tolerance occurs when a person needs a higher dose of THC to achieve the desired effect. People who become tolerant to THC may also experience unwanted effects and dependence. Healthdirect states that regular cannabis use can result in dependence and withdrawals. Tolerance happens to people who use THC repeatedly. It has been shown that after people are repeatedly exposed to THC, the effect of THC on the body reduces. This occurs because cannabinoid receptors in the body reduce their response to THC. For patients using medicinal cannabis, it has been recommended that they start with a low dose and increase the dose gradually over time (The TGA).
For chronic users of THC Gummies, there should be a clinical review if the user perceives they are no longer getting the effects. There are a number of different reasons people may perceive a loss of effect from their medicine. These reasons could be adverse effects from the medicine, other medicines or new/changing symptoms. They may have lost therapeutic benefit from the medicine, but they may have gained therapeutic benefit from other treatments or medicines. Dependence to THC can occur without a person developing an addiction to the substance.
Some regular users may restore sensitivity to THC by taking a planned “tolerance break” or reducing the THC Gummies used. Taking a break is not always appropriate for all medical cannabis patients. Symptoms of withdrawal can include cravings, anxiety, mood swings, and other psychological and physical symptoms that can be quite severe in the first few days and can last for weeks. If you are using medical cannabis for chronic pain or a chronic condition, it is important to speak to your prescriber before taking a break from medical cannabis, to determine if a gradual dose reduction is more appropriate.
This is especially the case if THC Gummies are part of a long-term or chronic treatment plan. Taking a break can lower tolerance, and returning to the previous dose of THC Gummies can result in more intense effects. The TGA stresses the importance of ongoing clinical assessment and monitoring for medicinal cannabis patients. Patients should speak to a health professional if they are unable to reduce their use of THC, are experiencing strong cravings, or continuing to increase their use despite adverse effects. Continuing to increase THC use may indicate dependence and problematic use. The goal of continued treatment should be to maximize the health benefits of treatment while minimizing the adverse effects, dependence, and tolerance.
Driving Laws, Workplace Safety & Compliance
Australian drivers face a higher degree of risk when consuming THC gummies, compared to other edibles. This is largely due to strict, state-based, zero-tolerance laws towards delta-9-THC. Most drivers using oral THC therapies will test positive well after the therapeutic effects of the drug have worn off. Delta-9-THC is legal to consume in many Australian states and Tasmania allows a legal defense for patients who can prove they are not actively impaired. New South Wales is considering legislation to provide similar legal defenses for THC patients. Patients using oral THC therapies face a higher degree of risk in other Australian states and, even in Tasmania, patients need to be aware of the laws and defenses to remain protected.
Complying with workplace safety laws increases responsibility for corporations to meet occupational health and safety regulations. High-risk work environments, like the aviation and heavy industries of manufacturing, construction and mining, have strict drug and alcohol policies because of the need to maintain an unimpaired workforce.
Because occupational screening tools, such as oral swabs and urine immunoassays, detect metabolic residues instead of current workplace intoxication, employees with a valid medical script are at risk of breaching a zero-tolerance enterprise agreement, and therefore face internal discipline and/or dismissal. Human Resources (HR) departments, along with occupational safety and health officers, evaluate employees’ fitness for work independently from federal medical assessments and determination. Prescribed oral medications require employees to make adaptations, adjustments and/or modifications to accommodate their condition at work, based on the decision of the occupational health physician.
However, employers are not required to make adjustments and/or modifications to accommodate employees, particularly if it endangers workplace safety or permits employees to perform high risk duties with psychoactive residues. It is the employees’ responsibility to adjust and/or modify their medication usage according to the limitations set by their workplace, including understanding the thresholds of corporate liability. Employees should also manage their medications to protect their employment and the safety of the public.
Can You Drive After Taking THC Gummies in Australia?
It is common to build a tolerance to THC Gummies. When a person builds a tolerance to THC Gummies, a person has to take a higher dose to get the same effects. Continuously taking a higher THC Gummies dose can result in adverse health effects and may increase dependence. Healthdirect states that frequent use of cannabis can result in dependence and withdrawal. Cannabis tolerance can be explained by the body adapting to the repeated exposure of cannabinoids. With THC exposure, over time the body’s response to THC can weaken. The TGA recommends a “start low, go slow” approach to see how the body responds to medical cannabis. The TGA recommends that prescribers take a person’s prior tolerance to medical cannabis, as well as prior THC buildup in the person’s body fat, to determine a person’s optimal medical cannabis dose. T
his means that a person who frequently used THC Gummies and is no longer experiencing the desired effects may not be truly experiencing a loss of therapeutic benefit to the medication and may need to be assessed by a healthcare professional to ensure the medicine is having the desired effects. The healthcare professional can assess the person’s symptom control, side effects to the medicine, as well as assess other medicines the person is taking. A person using THC Gummies to manage a medical condition should keep a record of how long it has been since they took the Gummies, the dose of the Gummies, how they are feeling, and side effects. This record can provide the prescribing healthcare professional with information on how the person is responding to treatment. It can also help people distinguish if their loss of therapeutic benefit to the medicine is real, and if their body is getting used to the medicine, or if their symptoms have changed. With a loss of therapeutic benefit, dependence can occur even if a person is not addicted to the THC Gummies.
Taking a planned “tolerance break” from THC Gummies can be an effective way to regain sensitivity for some regular users. However, taking a break is not always appropriate for all medical cannabis patients. Withdrawing THC suddenly can cause withdrawal symptoms. Some of these symptoms can include, but are not limited to, cravings, anxiety, sleep issues, appetite changes, mood swings, restlessness and nausea. These symptoms can last for weeks and can be most prominent during the first few days of withdrawing. For patients using medical cannabis to help manage chronic pain or other conditions, stopping THC Gummies may also cause a flare up of the chronic condition. Patients should discuss taking a break with their doctor to see if adjusting their treatment plan would be more appropriate.
If a patient needs to take a break from THC Gummies, it can also help to lower the dosage instead of stopping use all together. The tolerance to THC Gummies will decrease if a break is taken, and if THC Gummies are then reintroduced at the previous high dosage, it can increase the THC effects and make them unpleasant. The Therapeutic Goods Administration (TGA) of Australia notes the importance of ongoing monitoring of patients to assess the effectiveness of THC treatments as well as monitor potential adverse effects of treatment. If patients find they are experiencing adverse effects from THC as well as experiencing withdrawal symptoms if they stop use, this can indicate problematic or dependent use. The goal of treatment is not to increase or maintain THC exposure, but to help manage their condition as much as possible.
Workplace Drug Testing and Medicinal Cannabis Policies
THC Gummies can cause a stir in the workplace, even if the product is prescribed. Australian work health and safety (WHS) duties focus primarily on fitness for work and risk management. Safe Work Australia (SWA) says employees must take reasonable care to protect their own safety and must not adversely affect the safety of others. Employees must be fit and well enough to perform their duties. Employers are allowed to implement and enforce a drug and alcohol policy if there is a safety concern, and this is more applicable in the mining, aviation, transport and heavy-machinery industries. These policies and the related testing can be generally strict and essentially zero-tolerance. A medicinal cannabis prescription will not remove the requirements of an employer’s drug and alcohol policy.
A worker can have a prescribed THC Gummies and still not be able to perform safety-sensitive duties. Employers must balance their WHS obligations and industrial relations (IR) legislation and legislation related to workplace drug testing. Employees must understand a prescription and a workplace fitness assessment are separate. The TGA says that products containing medicinal cannabis can legally be prescribed via regulated paths, such as the Special Access Scheme (SAS) or Authorised Prescriber pathways. Lawful medical use of cannabis does not mean THC is permitted in all workplaces, and this is particularly the case when there are heights, machinery, vehicles, or other high-risk environments.
THC Gummies can affect your employment in different ways based on your job, your employer and the laws in your area. Policies relating to impairment in the workplace vary. In a standard office environment the employer may rely on a fitness-for-work policy. Other employers, particularly those in safety-sensitive industries, may have more stringent policies. Some occupations, such as mining, aviation, and heavy equipment operations, may rely on drug and alcohol testing as part of their risk management systems. Safe Work Australia states that workers may be tested for alcohol and illicit substances where there is the potential for a worker to cause a serious or significant injury or death. Also, some laws can prohibit an employee from being under the influence of legal or illegal substances.
Because of this, an employee cannot assume a prescription for a legal substance makes a positive drug test irrelevant. There are several ways to address this. The worker could contact their treating physician to see if they would recommend sedation or if the worker may have impairment or loss of fitness for duty. The worker could then contact their employer’s occupational health and safety department to answer any questions the worker may have about the employer’s policy. There are ways to address the legal access and the right to work while affected by THC.
International Travel with Prescribed Medicinal Cannabis
There are a number of restrictions when travelling internationally with prescribed medical cannabis, including various forms of THC. The use of prescribed medical cannabis is permitted on all domestic flights within Australia; however, the rules change when travelling internationally. The most important rule when travelling internationally is always to abide by the rules of the country you are visiting, as the Australian medical prescription has no bearing outside of Australia. Tetrahydrocannabinol (THC) is a prohibited narcotic in many countries, and the medical use of cannabis does not apply outside of Australia. It is highly recommended that patients contact the embassy or consulate of the country they are visiting well in advance to enquire about personal importation permits and the legal use of cannabis, as bringing cannabis products to a country that does not permit the use of cannabis products may have severe legal consequences, including arrest and detention.
Travellers returning to Australia, and some travellers transiting through certain international hubs, encounter strict customs controls administered by various agencies including the Office of Drug Control (ODC). As per the official Australian traveller’s exemption, residents can return with a three-month supply of prescribed medicine, as long as it is in the original pharmacy packaging with the labels intact, and they possess a letter from their prescribing doctor, a copy of their prescription, and a photo ID. Travellers must declare these to the Australian Border Force to avoid violations. It is illegal to have unlabelled medicine, to give medicine to travel companions, or to bring an amount that is greater than is required for the duration of the trip. Preparation, communication with foreign embassies, and management of documents allow patients to have peace of mind regarding unexpected legal issues when travelling.
With THC gummies, quality and consistency are key, and that requires a higher standard during pharmaceutical formulation and manufacturing processes than is required for typical candies. Medical-grade oral confections produced for patients in Australia undergo stringent compounding protocols, such as Therapeutic Goods Order No. 93 (TGO 93). Compounding pharmacists balance the gelatin or pectin base, emulsifiers, and carrier lipids, to evenly distribute cannabinoids in every batch. This batch process prevents hot spots, or uneven distribution of active ingredients. Each dose needs to contain the milligram amount stated on the label, and quality control needs to determine the active ingredient’s physical stability, moisture content, and resistance to degrade, to ensure safety during transport and storage.
This scientific process ensures that the product doesn’t rely on artificial preservatives or unverified synthetic additives to maintain shelf stability and integrity. Consumer education is important for Australians who use medicinal cannabis. The formulation of cannabis in edible products can cause delayed metabolism. This can take up to 2 hours. Users need to understand how to read dosing instructions so that they do not over-dose. For example, the pharmacokinetics (rate of absorption) of cannabis may depend on whether it is taken with or without food. Also, the quality of food may change how quickly and how much of the cannabis is absorbed. Sometimes a dose of a cannabis product may contain different concentrations of THC.
Cannabis has interactions with many other products. Therefore, it is important to keep cannabis with the other medicinal products away from food, in a cool, dry place. User education covers aspects of federal laws and rules and enables people to understand how to identify acceptable products and packaging, request or interpret product test results, and monitor treatment responses. The major emphasis of the Australian medicinal cannabis market is toward product quality and transparency and robust consumer education to ensure that consumers attain optimal therapy effect while health care providers remain certain of product safety and legality within the framework of the law.
Live Rosin vs. Distillate: What Goes Into Medicinal THC Gummies?
Decisions about solventless live rosin vs. refined distillate affect the base composition, terpene retention, and therapeutic output of medicinal THC gummies. Distillate gummies are made using highly refined distillate. Distillate is created by using advanced chemical separation techniques. The result is delta-9 THC with purity levels of 90% or higher. A major appeal of using distillate to create THC gummies is the neutral and predictable baseline for the pharmaceutical industry, and the fact that compounding pharmacists are able to make THC gummies in precise milligram doses while removing the plant’s natural taste.
The main drawback to using distillate to create THC gummies is the loss of minor cannabinoids and volatile terpenes. One upside to using live rosin to create THC gummies is that a solventless, mechanical process is used to extract the cannabinoids. A downside to using the mechanical process to create live rosin is that contaminants are not always removed and the terpene and cannabinoid profiles can vary batch to batch.The different extraction methods for THC gummies modify how human biology interacts with them in a variety of ways. Gummies made with distillate provide a simple, predictable, psychoactive effect. Live rosin gummies utilize the entourage effect.
The terpenes in the live rosin, when bound with THC, act as modulators and can better control the shape of the receptors, providing a more full body effect and a broader array of therapeutic benefits.When thinking of a therapeutic effect and as it pertains to inflammation and stiffness, a distillate isolate would certainly be more effective. However, for a therapeutic effect that is more full body, live rosin would be more appropriate.When thinking about the “effect profile” of a THC product, Australian medical professionals take this into consideration when suggesting an extraction method most appropriate for a given patient.
Understanding Certificates of Analysis (COAs) for Cannabis Products
Reading a Certificate of Analysis (COA) is a necessity for patients who want to verify the safety and composition of their prescribed THC gummies. A COA is a laboratory report issued by a third-party laboratory that tests a given product and describes the results. When reviewing an oral confection (gummy) COA, the first section to review is the cannabinoid profile. This section of the report states the amount (in mg) of the major active cannabinoids in the product. This can be stated in terms of mg per gram (of product) or mg per individual piece (of the product). If reviewing a COA that states the THC and CBD levels in mg, and the pharmacy label on the THC gummy states the strength as “10 mg THC,” then the patient is confirming that the THC level reported on the laboratory report matches the THC stated on the label. It is critical that the batch number stated on the prescription container is cross referenced to the batch number stated on the laboratory report.
It is also critical that the laboratory documentation is verified to validate that the extraction relies on full spectrum cannabis or THC, or if it’s an isolate. Having the laboratory documentation validates that patients are ingesting the correct therapeutic amount of cannabinoids and that there are no hidden discrepancies. Past potency, a comprehensive COA offers essential safety information by validating heavy metal testing, pesticide residue testing, and contamination by microbes. Medical products in Australia, subject to TGO 93, must meet stringent standards for safety of environmental toxins. The heavy metal test panel is used to detect lead, arsenic, cadmium, mercury, and other elements that the original cannabis plant may have absorbed from polluted soil or from equipment in the manufacturing process.
The pesticide testing and solvent residual testing verify that no agrochemicals or chemical extraction agents are left in the gelatin or pectin matrix. Various pathogenic tests are performed to check for salmonella and E. coli as well as mycotoxins. Learning how to interpret scientific data and reports empowers the patient to confirm the presence of contaminants, safety and legal compliance of their THC gummies. The state of the laboratory report can also tell when safe limits have been exceeded or if tests have been performed beyond their validity period.
Comparing Delivery Methods: Gummies vs. Oils, Sprays, and Vapes
When discussing the various medical cannabis delivery formats, bioavailability and speed of systemic onset are the most useful metrics. After a THC gummy is ingested, it travels through the digestive system, where it is broken down by the liver through first pass metabolism. The oral bioavailability of standard THC gummies is between 4-12%. The liver breaks standard delta-9-THC down to 11-hydroxy-THC. 11-hydroxy-THC creates deep, body-focused therapeutic effects, and lasts 8 hours or more. A faster systemic onset can be achieved via absorption through the mucus membranes in the mouth. This is seen with the use of sublingual THC sprays and oils. These formats bypass most of the digestive system and allow the THC to enter the blood stream through the mucus membranes of the mouth.
The onset of symptom control with sublingual sprays and oils is 15-45 minutes and the effect is less than THC gummies. The method of administration also impacts the bioavailability of the cannabinoid. A 2019 study demonstrated that dry herb vaporizers create a 30% bioavailability of the active cannabinoids. The fast acting nature of vaping allows for symptom control within minutes. The impact of the symptom control from vaping fades within 2-4 hours. Each delivery format of cannabis has its own pros and cons, and understanding these allow the patient to best meet their medical needs. THC gummies and medical oils work better for patients with chronic and constant conditions such as long term and recurring insomnia, chronic muscle spasticity and inflammatory conditions. For some patients, all day and all night stability is required.
THC gummies are preferred because they deliver a premeasured dose making them discreet as well as eliminating the need to measure doses or use complicated inhalation devices. Although THC gummies are not as effective as THC oils and sprays because of the difference in the rate of onset, and patients tend to have less control with gummies in comparison to oils and sprays, an overdose is still a higher risk, especially if the patient is not well informed and impatient about the result. To control inflammatory conditions, the administration method is of key importance. Therefore, Australian health professionals assess the specific characteristics of different drugs when prescribing different methods of administration so that patients are not only complying with therapeutic requirements but also with administrative requirements.
Common Myths and Misconceptions About THC Edibles in Australia
It is rumored that THC gummies are sold on websites like Amazon and Ebay. There are also rumors that you can buy them at your local stores. The rumors are not true. In Australia, THC products are Schedule 8 controlled drugs at the federal level. Local and online stores that sell THC-laced edibles are breaking the law and putting users at risk of arrest. The Australian Border Force (ABF) actively seizes packages from overseas that contain THC edibles. The ABF targets package shipments and air shipments. THC edibles are illegal to import, and consumers that attempt to import them can face penalties and arrest.
Medical users bypass the illegal gray market by going through proper channels to gain legal access to the products through licensed compounding pharmacies. The false belief that recreational edibles are legal gives people the false sense of security and predisposes them to break federal law and face legal consequences. There are other dangerous myths about the origin and safety of the chemicals in black market THC gummies. Many customers believe that illicit THC gummies are identical to THC gummies sold at pharmacies. In the black market, importers can rename or relabel THC products to mislead customers, and these products can contain dangerous and unexpected synthetic substances. These substances can be far more potent and dangerous than natural plant extracts.
Results from independent drug tests show there are unexpected and dangerous variations in the chemicals used to make THC edibles, as well as heavy metal contaminants and pesticide residues. Unlike legal and regulated Australian pharmaceutical products, which are strictly regulated and manufactured to contain the exact and correct dose, product variability leads to inconsistent dosing and unexpected side effects, like rapid and abnormal heart rate and psychological distress. Correcting these internet myths and misinformation protects vulnerable customers. Only prescription, compounding pharmacies in Australia are truly safe and adhere to Australian medicinal standards.
Skip to content
